Corona Remedies IPO Details
The key details of Corona Remedies’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹655.37 Cr |
| Price Range | ₹1,008 - ₹1,062 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 14 |
| Investment (cut-off price) | ₹14,868 |
| Pre IPO Promotor Holding | Update soon |
| Post IPO Promotor Holding | Update soon |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Corona Remedies IPO Timelines
The IPO process for Corona Remedies includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
08/12/2025
Start Date10/12/2025
End Date12/12/2025
Refund Initiation12/12/2025
Credit of Shares to Demat Ac15/12/2025
Listing DateCorona Remedies IPO Lot Size
The Corona Remedies IPO has a fixed lot size of 14 shares, at an upper price band of ₹1,062 per share. For retail investors, the minimum application is 14 shares (1 lot) amounting to ₹14,868, while the maximum is 182 shares (13 lots) worth ₹1,93,284. For Small HNI (S-HNI) investors, the minimum application is 196 shares (14 lots) worth ₹2,08,152, while the maximum is 938 shares (67 lots) amounting to ₹9,96,156. Big HNI (B-HNI) investors need to apply for at least 952 shares (68 lots), totaling ₹10,11,024.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹1,93,284 |
| S-HNI Minimum | 14 | 196 | ₹2,08,152 |
| S-HNI Maximum | 67 | 938 | ₹9,96,156 |
| B-HNI Minimum | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Subscription Status
The subscription status for Corona Remedies IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 0.00x | 0.81x | 0.92x | 1.41x | 0.64x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Corona Remedies IPO Company Financials
Corona Remedies reports robust performance in FY2026 June with Total Income of ₹348.56 crores, managing expenses at ₹276.76 crores, and achieving a strong PAT (Profit After Tax) of ₹46.20 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹891.10 | ₹756.07 | ₹84.93 |
| FY 2024 | ₹1,020.93 | ₹859.74 | ₹90.50 |
| FY 2025 | ₹1,202.35 | ₹956.44 | ₹149.43 |
| FY 2026 (3 M) | ₹348.56 | ₹276.76 | ₹46.20 |
About Company
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company engaged in developing, manufacturing, and marketing products across women’s healthcare, cardiology, pain management, urology, and other key therapeutic areas. As of June 30, 2025, its portfolio comprises 71 brands spanning women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty segments such as vitamins, minerals, nutrition, gastrointestinal, and respiratory care.
The company maintains a strong pan-India presence through a marketing and distribution network supported by 2,671 medical representatives across 22 states, enabling extensive engagement with healthcare professionals and hospitals. Corona Remedies operates two manufacturing facilities in Gujarat with a combined installed capacity of 1,285.44 million formulation units per year, supporting its growth and deep penetration in the Indian Pharmaceutical Market (IPM).
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2004 | Pharmaceuticals | Nirav Mehta |
Know Before Investing
Corona Remedies IPO Strengths
- Luxury Time specializes in distribution and retail of premium Swiss luxury watches, tapping into India’s growing high-end consumer market.
- The company operates exclusively in the high-margin luxury timepiece segment, benefiting from aspirational consumer trends and premium pricing power.
- Launch aligns with festive season demand for luxury goods and rising disposable incomes in urban India.
- Established presence in luxury goods distribution supports efficient inventory management and customer service.
- India’s luxury market expansion, driven by affluent millennials and international tourism recovery, supports sector upside.
Corona Remedies IPO Risks
- Economic slowdowns or reduced discretionary spending can sharply impact demand for high-priced watches.
- Setting up four new stores involves site selection, fit-outs, and staffing challenges that could lead to delays or cost overruns.
- Luxury watches require significant upfront capital for stock; slow-moving inventory ties up liquidity.
- Faces rivalry from global luxury brands, multi-brand outlets, and e-commerce platforms offering similar products.
- Operations likely centered in key urban markets, exposing business to localized economic or regulatory changes.
- Sourcing premium Swiss watches exposes margins to currency fluctuations and global supply disruptions.
Swot Analysis for Corona Remedies IPO
Strengths
Strong Domestic Positioning, Quality Manufacturing, Diversified Therapy Portfolio
Weaknesses
Domestic-Focused Revenue, Contract Manufacturing Dependence, MR-Heavy Cost Structure
Opportunities
Chronic Therapy Growth, Geographic Deepening, In-licensing & Partnerships
Threats
Intense Competition, Regulatory & Compliance Risk, Sectoral Policy Shifts
Company Details
Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
IPO Registar Details
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
FAQs
The key objectives of Corona Remedies IPO are:
- NA
JM Financial Ltd. , IIFL Capital Services Ltd. , Kotak Mahindra Capital Co. Ltd. are the book-running lead managers for the Corona Remedies IPO.
Corona Remedies IPO shows strong growth potential backed by its leadership in high growth chronic and women’s health therapies expanding field force and a robust pipeline of new launches. The upcoming hormone manufacturing facility and consistent outperformance of the Indian pharmaceutical market support multi year scalable domestic formulation growth.
The issue price for the Corona Remedies IPO is set between ₹1008 to ₹1062 per share.
To invest in one lot of Corona Remedies IPO, you need ₹14,112 at the lower price band (₹1008 per share) or ₹14,868 at the upper price band (₹1062 per share) for a lot size of 14 shares.
Corona Remedies IPO shares are scheduled to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on December 15, 2025.
Refund/unblocking of funds for Corona Remedies IPO will begin on December 12, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Corona Remedies IPO shares on listing day (December 15, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.